FDA said it is partnering with the European Medicines Agency (EMA) on regulatory strategies to facilitate the development of COVID-19 vaccines.

During a March 18 meeting, regulators discussed necessary preclinical data and the need to evaluate theoretical risk for vaccine-induced disease enhancement, while acknowledging the urgency of proceeding to human clinical trials with SARS-CoV-2 candidate vaccines

Related News Articles

Headline
The departments of Health and Human Services and Defense yesterday announced an agreement to purchase at least 105 million doses of a Pfizer omicron-…
Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response and Food and Drug Administration this week…
Headline
The Food and Drug Administration today announced it has revoked the emergency use authorizations for the Simoa Semi-Quantitative SARS-CoV-2 IgG Antibody…
Headline
The Centers for Disease Control and Prevention last night endorsed Moderna’s COVID-19 vaccine for children aged 6-17, as its advisory committee…
Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices today unanimously recommended Moderna’s COVID-19 vaccine for…
Blog
A recent article in the Washington Post “COVID bailout rescued some hospitals while enriching others” is wrong. The reality is that all of America’s hospitals…